Lupin Launches Generic Trizivir® Tablets in the US

              Lupin Launches Generic Trizivir® Tablets in the US

PR Newswire

MUMBAI and BALTIMORE, December 18, 2013

MUMBAI and BALTIMORE, December 18, 2013 /PRNewswire/ --

Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary
Lupin Pharmaceuticals Inc. has launched its Abacavir Sulfate, Lamivudine, and
Zidovudine Tablets, 300 mg (base) / 150 mg / 300 mg in the US after the US
District Court for the District of Delaware ruled that the Lupin's generic
version of Trizivir® did not infringe on patents. Lupin had earlier received
approval for the same.

Lupin's Abacavir Sulfate, Lamivudine Zidovudine 300mg (Base)/150mg/300mg
Tablets are the AB-rated generic equivalent of ViiV Healthcare's (ViiV)
Trizivir® Tablets, 300 mg (base) / 150 mg / 300mg and are indicated in
combination with other antiretrovirals or alone for the treatment of HIV-1
infection.

Lupin is the first applicant to file an ANDA for Trizivir® Tablets and as such
is entitled to 180 days of marketing exclusivity.

Trizivir® Tablets, 300 mg (base) / 150 mg / 300mg had annual U.S sales of
approximately US$ 111.6 million (IMS MAT Sep, 2013). 

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company producing and
developing a wide range of branded and generic formulations and APIs globally.
The Company is a significant player in the Cardiovascular, Diabetology,
Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global
leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US
(5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian
pharmaceutical company by revenues. The Company is also the fastest growing
top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2013, Lupin's Consolidated turnover and
Profit after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142
million (USD 242 million) respectively. Please visit http://www.lupinworld.com
for more information.

Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated
to delivering high-quality, affordable generic medicines and branded
formulations trusted by healthcare professionals and patients across
geographies. For more information, visit http://www.lupinpharmaceuticals.com

For more information, please contact -

Shamsher Gorawara
Head - Corporate Communications
Lupin Limited
Ph: +91-98-20-338-555
Email: shamshergorawara@lupinworld.com         

Safe Harbor Statement*Trizivir^®is a registered trademark of ViiV
Healthcare

SOURCE Lupin Ltd
 
Press spacebar to pause and continue. Press esc to stop.